Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith,

Slides:

Advertisements

Similar presentations

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Advertisements

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

by Henrik Frederiksen, and Kai Schmidt

Allogeneic Hematopoietic Cell Transplantation in Patients Age Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous.

Fenaux P et al. Lancet Oncol 2009;10(3):

One giant leap for pediatric AMKL

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Deep mining of the RBC proteome

Reproductive capacity in iron overloaded women with thalassemia major

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In.

Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic.

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

The real world of 'low-risk' MDS: early lessons from the EUMDS registry Theo de Witte, Louise de Swart, Alex Smith, Pierre Fenaux, Raphael Itzykson, Guillermo.

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL by Arnon P. Kater, Sabina.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL by Christian H. Geisler, Mars.

Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study by Andreas K. Øvlisen, Anders Oest,

Leonardo P. de Carvalho et al. BTS 2018;3:

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes by Abdullah Mahmood Ali, Yumin Huang,

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.

by Alex Aleshin, and Peter L. Greenberg

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

by Dana T. Lounder, Qiong Bin, Cristina de Min, and Michael B. Jordan

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL by Lina Hamadeh, Amir Enshaei, Claire Schwab,

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia by Jaime Sanz, Mi Kwon, Guiomar Bautista, Miguel.

Lacramioara Botezatu, Lars C

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group by Tao Wu, Yong Yang, Su-Yu.

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,

Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma by Marie-Hélène Delfau-Larue, Axel.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study by Ada Gillissen, Thomas van den Akker,

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

by Mieke Aldenhoven, Brigitte T. A. van den Broek, Robert F

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Revised International Prognostic Scoring System for Myelodysplastic Syndromes by Peter L. Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo.

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine by Raphaelle Fanciullino, Laure Farnault, Mélanie.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

by Jens Kjeldsen-Kragh, Thomas L

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML by Renato Bassan, Tamara Intermesoli, Arianna.

by David Deambrosis, Su Han Lum, Ryan M

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Impact of age on clinical risk scores in follicular lymphoma

by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher,

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML by Jorge E. Cortes, Martin S. Tallman, Gary.

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.

Cold agglutinin disease

Presentation transcript:

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith, Argiris Symeonidis, Eva Hellström-Lindberg, Guillermo Sanz, Jaroslav Čermák, Reinhard Stauder, Chiara Elena, Ulrich Germing, Moshe Mittelman, Saskia Langemeijer, Krzysztof Mądry, Aurelia Tatic, Mette Skov Holm, Antonio Medina Almeida, Aleksandar Savic, Njetočka Gredelj Šimec, Elisa Luño, Dominic Culligan, Agnes Guerci-Bresler, Luca Malcovati, Corine van Marrewijk, David Bowen, Theo de Witte, and Pierre Fenaux BloodAdv Volume 2(16):2079-2089 August 28, 2018 © 2018 by The American Society of Hematology

Raphael Itzykson et al. Blood Adv 2018;2:2079-2089 © 2018 by The American Society of Hematology

Prognostic impact of relative drop in platelets and neutrophils. Prognostic impact of relative drop in platelets and neutrophils. Kaplan-Meier plots of OS from landmark (with 95% CIs) according to 6-month relative platelet (A) and neutrophil (B) drop. CIP since landmark according to 6-month platelet (C) and neutrophil (D) drop. Blue, relative platelet or neutrophil drop ≤25%; red, relative platelet or neutrophil drop >25%. Raphael Itzykson et al. Blood Adv 2018;2:2079-2089 © 2018 by The American Society of Hematology

Prognostic impact of relative platelet drop in defined subgroups. Prognostic impact of relative platelet drop in defined subgroups. Forest plot of HRs of relative platelet drop >25% according to baseline IPSS-R risk and absolute platelet count at inclusion and landmark. Raphael Itzykson et al. Blood Adv 2018;2:2079-2089 © 2018 by The American Society of Hematology

Design of the 6-month EUMDS classifier. Design of the 6-month EUMDS classifier. Kaplan-Meier plots of OS (A) and CIP (B) from landmark according to the 6-month EUMDS classifier based on platelet drop >25% and RBC-TD at landmark. (C). Forest plots of HRs of each additional criterion in the 6-month EUMDS classifier according to baseline IPSS-R risk in the landmark cohort. Blue, no criteria; red, either criteria, green, both criteria. Raphael Itzykson et al. Blood Adv 2018;2:2079-2089 © 2018 by The American Society of Hematology

Validation of the 6-month EUMDS classifier. Validation of the 6-month EUMDS classifier. Kaplan-Meier plots of OS in the external validation cohort (n = 335) according to platelet drop >25% at the 6-month landmark (blue, relative platelet drop ≤25%; red, relative platelet drop >25%) (A) and the 6-month EUMDS classifier (B). (C) CIP according to the 6-month EUMDS classifier. (B-C) Blue, no criteria; red, either criteria; green: both criteria. Raphael Itzykson et al. Blood Adv 2018;2:2079-2089 © 2018 by The American Society of Hematology